Allo-SCT from an HLA related or unrelated donor is the first line treatment for newly diagnosed patients with BMFS younger than 40 years, and for older patients that failed immunosuppressive therapy. Cohort retrospective analysis of BMFS patients receiving Allo-SCT in a mixed (pediatric-adult) transplant center in Bogota, Colombia, are reported. Log-rank tests(Lrt) analyses were used to determine the effects of age, conditioning regimen and year of treatment on survival. Between January 1993 and August 2011, 74 transplants were performed in 70 patients(52 acquired SAA,16 Fanconi Anemia and 2 pure red cell aplasia). Table 1 reflects patients and transplant characteristics. 70 grafts were obtained from HLA identical siblings, 3 from unrelated CBU and 1 from a haploidentical sibling. Conditioning regimens used were: RIC Cy-Flu-ATG(22), Cy-ATG(33) and Cy(12). 4 patients were conditioned with Campath containing regimens and 3 with other. Before 2004 most patients received Cs and MTX as GVHD prophylaxis, after 2004 Cs and MMF was used in the majority.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.